BCRX (BioCryst Pharmaceuticals) LT-Debt-to-Total-Asset: 1.75 (As of Mar. 2026)

What is BioCryst Pharmaceuticals LT-Debt-to-Total-Asset?

BioCryst Pharmaceuticals BCRX +4.60% 66 LT-Debt-to-Total-Asset is 1.75 as of Mar. 2026. GuruFocus rates BCRX with a GF Score™ of 66/100 and a GF Value™ of $12.75 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioCryst Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 1.75.

BioCryst Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2025 (1.65) to Mar. 2026 (1.75). It may suggest that BioCryst Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

BioCryst Pharmaceuticals (NAS:BCRX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioCryst Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

BioCryst Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals LT-Debt-to-Total-Asset Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

1.01

1.34

1.59

1.64

0.85

BioCryst Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															1.65	1.53	1.44	0.85	1.75

66GF Score

BioCryst Pharmaceuticals Inc BCRX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioCryst Pharmaceuticals LT-Debt-to-Total-Asset Calculation

BioCryst Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	437.245	/	514.158
	=	0.85

BioCryst Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	814.673	/	465.052
	=	1.75

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 1.75 mean?

BioCryst Pharmaceuticals (BCRX) has a LT-Debt-to-Total-Asset of 1.75 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioCryst Pharmaceuticals and its competitors.

Is BioCryst Pharmaceuticals' LT-Debt-to-Total-Asset too high?

BioCryst Pharmaceuticals' current LT-Debt-to-Total-Asset is 1.75. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does BioCryst Pharmaceuticals' LT-Debt-to-Total-Asset compare to SUPN and PBH?

BioCryst Pharmaceuticals' LT-Debt-to-Total-Asset of 1.75 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current LT-Debt-to-Total-Asset is 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioCryst Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.75, compared to a current price of $9.99 — trading 21.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 1.75. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current LT-Debt-to-Total-Asset is 1.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.99 is trading 21.6% below its estimated GF Value™ of $12.75. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

LT-Debt-to-Total-Asset: 1.75
GF Value™: $12.75 vs. price of $9.99 (21.6% below fair value)
GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCryst Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SUPN PBH AMLX RGC ANIP TRLV HROW PRGO XERS PAHC XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges BCRX:Mexico BO1:Germany

Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

66GF Score

Get the complete analysis for BCRX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.99

Price

$12.75

GF Value

View BCRX Analysis

See LT-Debt-to-Total-Asset data for all stocks →